AMVAX B 1ML INJ (Heb B) at Chughtai Lab

AMVAX B 1ML INJ (Heb B) at Chughtai Lab

The AMVAX B 1ML INJ (Heb B) is a sterile, non-infectious recombinant DNA vaccine administered for active immunization against infection caused by all known subtypes of the Hepatitis B virus (HBV). Hepatitis B is a highly contagious, potentially life-threatening viral infection that targets the liver, leading to acute illness, chronic carrier states, progressive liver cirrhosis, and hepatocellular carcinoma (primary liver cancer). The vaccine contains purified hepatitis B surface antigen (HBsAg) produced by recombinant DNA technology in yeast cells (Saccharomyces cerevisiae). This advanced biotechnology ensures that the vaccine is entirely free of blood-derived products, eliminating any risk of viral transmission from the vaccine itself.

When administered at Chughtai Lab, Pakistan’s premier diagnostic and immunization network, patients receive the highest standard of clinical care. The vaccine works by stimulating the body’s immune system to produce specific neutralizing antibodies (anti-HBs) against the hepatitis B surface antigen. These antibodies provide long-term, highly effective protection by neutralizing the virus if exposure occurs. Immunization is the most effective preventive healthcare measure available to control and eventually eradicate Hepatitis B transmission. Chughtai Lab maintains an uncompromised cold chain system to preserve the potency and efficacy of the vaccine from storage to administration, ensuring optimal immunogenicity for every patient.

Clinical Procedure: What to Expect

Patient Preparation

Proper preparation is essential to ensure a safe and comfortable vaccination experience. Patients undergoing immunization with AMVAX B 1ML INJ (Heb B) at Chughtai Lab should observe the following guidelines:

• No Fasting Required: There is no need to fast before receiving the vaccine. Patients are encouraged to eat a light meal and stay hydrated to prevent dizziness or vasovagal syncope.
• Medical History Disclosure: Inform the healthcare provider of any known allergies, particularly severe allergic reactions (anaphylaxis) to yeast or any component of the vaccine.
• Current Health Status: Disclose any active moderate-to-severe acute illnesses, with or without fever. Minor illnesses, such as a mild cold or low-grade fever, do not require postponing the vaccination.
• Bleeding Disorders: Inform the nurse if you have a history of bleeding disorders (such as hemophilia) or are taking anticoagulant medications (blood thinners), as this may increase the risk of bruising at the injection site.
• Pregnancy and Lactation: Inform the clinician if you are pregnant, planning to become pregnant, or breastfeeding. While recombinant vaccines are generally considered safe, a clinical benefit-risk assessment is standard practice.

During the Procedure

The administration of the AMVAX B 1ML INJ (Heb B) vaccine at Chughtai Lab follows strict clinical protocols to ensure patient safety and comfort:

Upon arrival, the clinical staff will verify the patient’s identity, medical history, and vaccination schedule. The patient is comfortably seated in a designated private immunization area. The nurse inspects the vaccine vial to confirm its integrity, expiration date, and correct storage temperature. The injection site, typically the deltoid muscle of the upper arm in adults and older children, is thoroughly cleansed with an antiseptic alcohol swab and allowed to air dry.

Using a sterile, single-use syringe, the nurse administers a 1ml dose of the vaccine intramuscularly at a 90-degree angle. Intramuscular administration is crucial, as subcutaneous or intradermal injection can result in a suboptimal immune response. The procedure takes only a few seconds and involves a brief, mild pinching sensation. After the injection, gentle pressure is applied to the site with a sterile cotton swab. Patients are advised to remain in the waiting area for 15 to 20 minutes post-injection to monitor for any immediate, rare allergic reactions, ensuring immediate medical assistance is available if needed.

When is a AMVAX B 1ML INJ (Heb B) Performed?

Occupational Exposure in Healthcare Settings

Healthcare professionals, including doctors, nurses, laboratory technologists, dentists, and emergency responders, face a high risk of occupational exposure to bloodborne pathogens. Accidental needle-stick injuries, mucosal splashes, or contact with contaminated surgical instruments can transmit the Hepatitis B virus. Physicians strongly recommend the AMVAX B vaccine series for all healthcare workers to establish protective antibody titers, safeguarding them from workplace-acquired infections and preventing nosocomial transmission to vulnerable patients.

High-Risk Lifestyle and Environmental Exposures

Individuals with specific lifestyle factors or environmental exposures are at an elevated risk of contracting Hepatitis B. This includes individuals with multiple sexual partners, those seeking treatment for sexually transmitted infections (STIs), household contacts or sexual partners of HBsAg-positive individuals, and people who inject drugs. Immunization with AMVAX B provides a critical immunological barrier, breaking the chain of transmission and protecting individuals from high-risk exposures in their daily environments.

Patients with Chronic Medical Conditions

Physicians routinely request Hepatitis B vaccination for patients diagnosed with chronic medical conditions that compromise their health or require frequent medical interventions. This includes patients with chronic kidney disease (especially those undergoing hemodialysis), individuals with chronic liver diseases (such as Hepatitis C, cirrhosis, or non-alcoholic fatty liver disease), and patients with diabetes mellitus. Protecting these individuals from Hepatitis B is vital, as co-infection or acute liver injury can lead to rapid hepatic decompensation and life-threatening complications.

International Travel to Endemic Regions

Travelers planning to visit regions with high or intermediate prevalence rates of Hepatitis B (such as parts of Sub-Saharan Africa, East Asia, the Amazon basin, and certain areas of the Middle East) should receive the AMVAX B vaccine series. The risk increases significantly for travelers who may require medical care, receive dental treatment, or engage in activities involving blood or bodily fluid contact while abroad. Completing the vaccine series prior to departure ensures robust, long-lasting immunity during international travel.

Post-Exposure Prophylaxis and Prevention of Transmission

In cases of known or suspected exposure to the Hepatitis B virus—such as through sexual assault, accidental needle-stick injuries, or mucosal exposure to infectious blood—the AMVAX B vaccine is administered as part of a post-exposure prophylaxis (PEP) protocol. When given promptly, often in combination with Hepatitis B Immune Globulin (HBIG), the vaccine stimulates the rapid production of active antibodies, preventing the virus from establishing a chronic infection in the host’s hepatocytes.

What Does a AMVAX B 1ML INJ (Heb B) Detect?

As an active immunizing agent, the AMVAX B 1ML INJ (Heb B) does not detect disease; rather, it stimulates, establishes, and maintains protective immunological parameters within the patient’s body. The clinical parameters, protective mechanisms, and safety indicators associated with this vaccine include:

• Active Immunization: Stimulates the host immune system to produce endogenous antibodies against the Hepatitis B virus.
• HBsAg Specificity: Targets the surface antigen of the virus, preventing viral attachment and entry into host liver cells.
• Humoral Immune Response: Triggers B-lymphocyte activation and differentiation into antibody-secreting plasma cells.
• Anti-HBs Antibody Production: Promotes the generation of quantitative protective antibody levels in the serum.
• Seroconversion Efficacy: Achieves a high seroconversion rate, typically exceeding 95% in healthy adults after a complete three-dose series.
• Immunological Memory: Establishes long-lived memory B and T cells that provide rapid, secondary immune responses upon future viral exposure.
• Prevention of Acute Hepatitis B: Protects against the acute clinical manifestations of HBV, including jaundice, dark urine, and extreme fatigue.
• Prevention of Chronic Carrier State: Eliminates the risk of becoming a chronic asymptomatic carrier capable of transmitting the virus.
• Prevention of Liver Cirrhosis: Protects against the chronic inflammatory processes that lead to extensive hepatic scarring and fibrosis.
• Prevention of Hepatocellular Carcinoma: Acts as an indirect anti-cancer vaccine by preventing the primary viral cause of liver cancer.
• Prevention of Hepatitis D Co-infection: Since the Hepatitis D virus requires the outer envelope of HBV to replicate, immunization effectively prevents HDV infection.
• Protection of Hemodialysis Patients: Provides tailored immunological defense for patients undergoing renal replacement therapy.
• Protection of Immunocompromised Hosts: Offers a vital shield for patients with suppressed immune systems, often managed with specialized dosing.
• Reduction of Community Transmission: Contributes to herd immunity, reducing the overall reservoir of the virus within the population.
• Safe Co-administration: Can be safely administered concurrently with other standard vaccines at separate injection sites.
• Minimal Local Reactogenicity: Demonstrates a highly favorable safety profile with minimal, self-limiting local tissue inflammation.
• Absence of Viral Replication: Contains no live viral particles, ensuring zero risk of vaccine-induced viral replication or disease.
• Long-Term Persistence: Provides durable protection that often lasts for decades, eliminating the routine need for booster doses in healthy individuals.
• Verification via Titer Testing: Efficacy can be clinically verified post-vaccination using quantitative Anti-HBs blood tests.
• Cold Chain Verification: Preserves vaccine potency through strict adherence to international storage standards (2°C to 8°C).

Turnaround Time and Report Access at Chughtai Lab

At Chughtai Lab, the administration of the AMVAX B 1ML INJ (Heb B) vaccine is documented immediately. Upon receiving the injection, patients are provided with an official, physical immunization card detailing the vaccine name, batch number, manufacturer, date of administration, and the scheduled dates for subsequent doses. This physical record is crucial for tracking the completion of the multi-dose series (typically administered at 0, 1, and 6 months).

In addition to the physical card, Chughtai Lab integrates all immunization records into its secure digital portal. Patients can access their vaccination history online through the Chughtai Lab website or mobile application. This digital record is permanently stored and can be downloaded or printed at any time, providing convenient proof of immunization for employment, university admissions, or international travel requirements. Automated SMS reminders are also sent to the patient’s registered mobile number to ensure timely administration of booster doses.

AMVAX B 1ML INJ (Heb B) Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Vaccine Composition	Sterile, recombinant HBsAg protein; free of live viral DNA.	Compromised vaccine integrity due to improper storage or freezing.
Administration Route	Intramuscular injection in the deltoid muscle.	Accidental subcutaneous or intradermal injection, reducing efficacy.
Post-Vaccine Antibody Titer (Anti-HBs)	Concentration ≥ 10 mIU/mL, indicating protective immunity.	Concentration < 10 mIU/mL, indicating non-response or incomplete series.
Injection Site Reaction	Mild, transient soreness, erythema, or slight swelling resolving in 48 hours.	Severe localized pain, persistent swelling, abscess, or cellulitis (rare).
Systemic Response	No systemic symptoms or mild, self-limiting low-grade fever.	High-grade fever, severe headache, or immediate anaphylactic reaction (extremely rare).
Immunization Schedule Compliance	Completion of all three recommended doses (0, 1, and 6 months).	Incomplete or delayed dosing, leading to suboptimal long-term immunity.
Vaccine Storage Temperature	Maintained strictly within the cold chain range of 2°C to 8°C.	Exposure to freezing temperatures or excessive heat, inactivating the antigen.
Target Patient Immune Status	Immunocompetent individual with a robust, protective antibody response.	Blunted or absent antibody response in severely immunocompromised individuals.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for AMVAX B 1ML INJ (Heb B)?

• Strict Cold Chain Integrity: Chughtai Lab utilizes advanced medical refrigeration systems to maintain the vaccine strictly between 2°C and 8°C, ensuring maximum potency.
• Highly Qualified Nursing Staff: Vaccinations are administered by trained, certified clinical nurses who follow international protocols for patient safety and comfort.
• Authentic Sourcing: All vaccines, including AMVAX B, are sourced directly from authorized pharmaceutical distributors to guarantee authenticity.
• Digital Immunization Records: Access your complete vaccination history anytime via the secure Chughtai Lab online portal and mobile app.
• Automated Reminders: Receive timely SMS notifications for your subsequent vaccine doses to ensure you complete the immunization schedule.
• Convenient Home Vaccination: Chughtai Lab offers professional home vaccination services, bringing clinical-grade healthcare directly to your doorstep.
• State-of-the-Art Diagnostics: Easily combine your vaccination with post-vaccine Anti-HBs titer testing at any of Chughtai Lab’s nationwide locations.
• Commitment to Patient Safety: Every vaccination center is equipped with emergency protocols to manage rare immediate allergic reactions safely and effectively.